Related Experiment Videos
Long-term management of splenic sequestration in children with sickle cell disease
T R Kinney1, R E Ware, W H Schultz
1Department of Pediatrics, Duke University Medical Center, Durham, North Carolina 27710.
Insights
Splenic sequestration crisis in children with sickle cell disease can occur even with low hemoglobin S levels. Transfusion therapy showed no significant benefit in preventing recurrent splenic sequestration compared to observation.
Area of Science:
- Pediatric Hematology
- Sickle Cell Disease Management
- Clinical Pediatrics
Background:
- Sickle cell disease (SCD) is a genetic blood disorder.
- Splenic sequestration crisis is a serious complication of SCD.
- Understanding SCD complications is crucial for effective patient care.
Purpose of the Study:
- To review management strategies for splenic sequestration crisis in pediatric SCD patients.
- To analyze the clinical course of children experiencing splenic sequestration crisis.
- To evaluate the efficacy of transfusion therapy in preventing recurrent splenic sequestration.
Main Methods:
- Retrospective case series of 23 children with SCD and splenic sequestration crisis.
- Analysis of management approaches including transfusion therapy and observation.
- Assessment of patient outcomes and recurrence of splenic sequestration.
Main Results:
- Splenic sequestration crisis can occur when hemoglobin S is less than 30% of total hemoglobin.
- Recurrent splenic sequestration rates were similar between transfusion and observation groups.
- Short-term transfusion programs demonstrated limited benefit in preventing recurrence.
Conclusions:
- Hemoglobin S percentage alone may not predict splenic sequestration crisis.
- Observation may be as effective as transfusion therapy for preventing recurrent splenic sequestration.
- Current transfusion protocols for preventing recurrent splenic sequestration in SCD may require re-evaluation.
Abstract:
We describe our experience with 23 children with sickle cell disease and splenic sequestration crisis, emphasizing our management approaches and the patients' subsequent clinical courses. Our data illustrate that sequestration crisis may occur despite a reduction in hemoglobin S concentration to less than 30% of the total hemoglobin mass. In addition, the risk of recurrent splenic sequestration was similar for patients who received transfusion therapy and for those who were simply observed. We conclude that a short-term transfusion program to prevent recurrent splenic sequestration is of limited benefit.